首页 > 最新文献

Allergy & Rhinology最新文献

英文 中文
Incidence of Olfactory Dysfunction in Patients with COVID-19 in a Tertiary Hospital in Saudi Arabia. 沙特某三级医院新冠肺炎患者嗅觉功能障碍发生率分析
IF 2.2 Q3 Medicine Pub Date : 2022-11-25 eCollection Date: 2022-01-01 DOI: 10.1177/21526575221140809
Rayan Alfallaj, Ghada AlSkait, Nouf Alamari, Lama Alfawzan, Mohammed Abualgasem, Naif H Alotaibi, Ibrahim Sumaily, Ibrahim Alarifi, Saad Alsaleh

Background: Coronavirus disease (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2, a novel virus that emerged in China in December 2019. In many cases of COVID-19, olfactory dysfunction (OD) is the only symptom.

Objectives: This study aimed to examine the incidence of OD in patients with COVID-19 and identify an association between OD and COVID-19-related morbidity and admission.

Design: This was a cross-sectional study.

Methods: Real-time reverse transcription polymerase chain reaction-confirmed cases of COVID-19 from the Security Forces Hospital electronic registry from June 2020 to September 2020 were included in our study. Data on medical background, severity of the disease, and other related factors were collected through phone calls and electronic healthcare systems and analyzed to investigate OD in the participants.

Results: Of the participants, 68% had OD, with a mean recovery time of 18 days and a mean follow-up time of 129 days (76-211 days). OD was negatively correlated with admission and morbidity.

Conclusion: OD is a common presentation of COVID-19 and is more prevalent in mild cases of infection.

背景:冠状病毒病(COVID-19)是由2019年12月在中国出现的新型病毒——严重急性呼吸综合征冠状病毒2型引起的。在许多COVID-19病例中,嗅觉功能障碍(OD)是唯一的症状。目的:本研究旨在研究COVID-19患者的OD发生率,并确定OD与COVID-19相关发病率和住院率之间的关系。设计:这是一项横断面研究。方法:选取安全部队医院2020年6月至2020年9月电子登记中实时逆转录聚合酶链反应确诊的COVID-19病例为研究对象。通过电话和电子医疗系统收集医学背景、疾病严重程度和其他相关因素的数据,并对其进行分析,以调查参与者的用药过量情况。结果:68%的参与者有吸毒过量,平均恢复时间为18天,平均随访时间为129天(76-211天)。用药过量与住院率和发病率呈负相关。结论:OD是COVID-19的常见表现,在轻症感染中更为常见。
{"title":"Incidence of Olfactory Dysfunction in Patients with COVID-19 in a Tertiary Hospital in Saudi Arabia.","authors":"Rayan Alfallaj,&nbsp;Ghada AlSkait,&nbsp;Nouf Alamari,&nbsp;Lama Alfawzan,&nbsp;Mohammed Abualgasem,&nbsp;Naif H Alotaibi,&nbsp;Ibrahim Sumaily,&nbsp;Ibrahim Alarifi,&nbsp;Saad Alsaleh","doi":"10.1177/21526575221140809","DOIUrl":"https://doi.org/10.1177/21526575221140809","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2, a novel virus that emerged in China in December 2019. In many cases of COVID-19, olfactory dysfunction (OD) is the only symptom.</p><p><strong>Objectives: </strong>This study aimed to examine the incidence of OD in patients with COVID-19 and identify an association between OD and COVID-19-related morbidity and admission.</p><p><strong>Design: </strong>This was a cross-sectional study.</p><p><strong>Methods: </strong>Real-time reverse transcription polymerase chain reaction-confirmed cases of COVID-19 from the Security Forces Hospital electronic registry from June 2020 to September 2020 were included in our study. Data on medical background, severity of the disease, and other related factors were collected through phone calls and electronic healthcare systems and analyzed to investigate OD in the participants.</p><p><strong>Results: </strong>Of the participants, 68% had OD, with a mean recovery time of 18 days and a mean follow-up time of 129 days (76-211 days). OD was negatively correlated with admission and morbidity.</p><p><strong>Conclusion: </strong>OD is a common presentation of COVID-19 and is more prevalent in mild cases of infection.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/f4/10.1177_21526575221140809.PMC9703475.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40491210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Inverted Papilloma of the Middle Ear: Two New Cases and Systematic Review. 中耳内翻性乳头状瘤:2例新病例及系统回顾。
IF 2.2 Q3 Medicine Pub Date : 2022-10-26 eCollection Date: 2022-01-01 DOI: 10.1177/21526575221130711
Peter L Miller, Erika Walsh, Do-Yeon Cho, Bradford A Woodworth, Jessica W Grayson

Introduction: Inverted papillomas of the middle ear are extremely rare tumors that carry an increased risk of recurrence and malignant transformation. There are currently 59 cases of middle ear inverted papillomas reported in the literature. The objective in this study was to systematically evaluate outcomes regarding middle ear inverted papillomas with respect to demographics, anatomical tumor sites, malignant transformation status, recurrence rate and HPV status.

Study design: Retrospective case series and systematic review.

Methods: A systematic review was completed on June 25, 2020 with a search strategy including PubMed, Embase, Scopus and Google Scholar. This revealed 181 articles. Full-text review was completed, and 66 articles were included. 115 articles were eliminated due to duplication of articles from databases, article titles not applicable to the aims of the systematic review and articles describing inverted papilloma of body sites other than middle ear.

Discussion: Thirty-one cases of primary inverted papillomas of the middle ear were found in the literature with an additional 26 cases of secondary tumors. Four case reports did not specify primary versus secondary. The malignant transformation rate was 34.4% with a 53.6% recurrence rate. Treatment of middle ear inverted papillomas is primarily surgical with adjuvant radiation therapy considered for patients with recurrence or malignant transformation. Frequent clinical follow up of these patients is critical due to the increased rate of recurrence and malignant transformation.

Conclusion: Inverted papillomas of the middle ear are rare tumors that carry a high risk of recurrence and malignant transformation necessitating complete resection and frequent clinical follow up.

简介:中耳内翻性乳头状瘤是一种极为罕见的肿瘤,其复发和恶性转化的风险较高。目前文献报道了59例中耳内翻性乳头状瘤。本研究的目的是系统地评估中耳内翻性乳头状瘤在人口统计学、肿瘤解剖部位、恶性转化状态、复发率和HPV状态方面的结果。研究设计:回顾性病例系列和系统评价。方法:系统评价于2020年6月25日完成,检索策略包括PubMed、Embase、Scopus和Google Scholar。这显示了181篇文章。完成全文审查,纳入66篇文章。115篇文章被淘汰,原因是数据库中的文章重复,文章标题不符合系统评价的目的,以及描述中耳以外身体部位内翻性乳头状瘤的文章。讨论:文献中发现原发性中耳内翻性乳头状瘤31例,继发性肿瘤26例。4例病例报告未明确原发性和继发性。恶性转化率34.4%,复发率53.6%。中耳内翻性乳头状瘤的治疗主要是手术治疗,对于复发或恶性转化的患者考虑辅助放射治疗。由于复发率和恶性转化的增加,频繁的临床随访对这些患者至关重要。结论:中耳内翻性乳头状瘤是一种复发、恶性转化风险高的罕见肿瘤,需要进行完全切除和频繁的临床随访。
{"title":"Inverted Papilloma of the Middle Ear: Two New Cases and Systematic Review.","authors":"Peter L Miller,&nbsp;Erika Walsh,&nbsp;Do-Yeon Cho,&nbsp;Bradford A Woodworth,&nbsp;Jessica W Grayson","doi":"10.1177/21526575221130711","DOIUrl":"https://doi.org/10.1177/21526575221130711","url":null,"abstract":"<p><strong>Introduction: </strong>Inverted papillomas of the middle ear are extremely rare tumors that carry an increased risk of recurrence and malignant transformation. There are currently 59 cases of middle ear inverted papillomas reported in the literature. The objective in this study was to systematically evaluate outcomes regarding middle ear inverted papillomas with respect to demographics, anatomical tumor sites, malignant transformation status, recurrence rate and HPV status.</p><p><strong>Study design: </strong>Retrospective case series and systematic review.</p><p><strong>Methods: </strong>A systematic review was completed on June 25, 2020 with a search strategy including PubMed, Embase, Scopus and Google Scholar. This revealed 181 articles. Full-text review was completed, and 66 articles were included. 115 articles were eliminated due to duplication of articles from databases, article titles not applicable to the aims of the systematic review and articles describing inverted papilloma of body sites other than middle ear.</p><p><strong>Discussion: </strong>Thirty-one cases of primary inverted papillomas of the middle ear were found in the literature with an additional 26 cases of secondary tumors. Four case reports did not specify primary versus secondary. The malignant transformation rate was 34.4% with a 53.6% recurrence rate. Treatment of middle ear inverted papillomas is primarily surgical with adjuvant radiation therapy considered for patients with recurrence or malignant transformation. Frequent clinical follow up of these patients is critical due to the increased rate of recurrence and malignant transformation.</p><p><strong>Conclusion: </strong>Inverted papillomas of the middle ear are rare tumors that carry a high risk of recurrence and malignant transformation necessitating complete resection and frequent clinical follow up.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/2e/10.1177_21526575221130711.PMC9618760.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40443701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management Strategy of Intracranial Complications of Sinusitis: Our Experience and Review of the Literature. 鼻窦炎颅内并发症的处理策略:我们的经验及文献复习。
IF 2.2 Q3 Medicine Pub Date : 2022-09-25 eCollection Date: 2022-01-01 DOI: 10.1177/21526575221125031
Bassel Hallak, Salim Bouayed, Joseph André Ghika, Pedro S Teiga, Vincent Alvarez

Objective: Sinusitis or rhinosinusitis is a very common disease worldwide, and in some cases, it leads to intracranial complications (ICS). These are more common in immunocompromised patients or with underlying comorbidities, but even healthy individuals, can be affected. Nowadays, ICS have become less common thanks to improved antibiotic therapies, radiological diagnostic methods, surgical techniques and skills. Nonetheless, they can still cause significant morbidity and mortality. For this reason, management of these complications requires a multidisciplinary approach to plan and customize treatment options. This paper presents our strategy in the management of a series of intracranial complications induced by acute sinusitis and compares our experience and outcomes with the literature.

Study design: Single institute experience, retrospective analysis of cases series and literature review.

Methods: Adult and child patients who were treated for ICS in the Department of Otorhinolaryngology at Sion Hospital, in Switzerland from 2016 to 2020 were included. Their symptoms, medical history, clinical and radiological findings, treatment, and outcome were documented.

Results: Eight patients (6 males- 2 females) aged from 14 to 88 y.o., were enrolled. None had any previous history of chronic, or recurrent sinusitis. Moreover, very few presented specific rhinological symptoms, but with neurological or other symptoms. Computed tomography (CT) and Magnetic Resonance Imaging (MRI) were used to confirm the diagnosis of all ICS. All types of known intracranial complications were observed in our cohort with a wide range of extension and severity of sinusitis. A multidisciplinary approach with individual treatments was tailored to each patient. Outcomes were favorable in almost all patients with neither recurrence, nor neurological sequels being observed in the follow-up. Only one patient was lost due to fatal complications of advanced lung cancer.

Conclusion: ICS remain a challenging clinical problem due to substantial associated morbidity and mortality. The incidence of these complications is relatively low. Therapeutical management guidelines are lacking. Early detection and multidisciplinary approach are key to successful treatment.

目的:鼻窦炎或鼻鼻窦炎是一种非常常见的疾病,在某些情况下,它会导致颅内并发症(ICS)。这些在免疫功能低下患者或伴有潜在合并症的患者中更为常见,但即使是健康个体也可能受到影响。如今,由于抗生素治疗、放射诊断方法、手术技术和技能的改进,ICS已经变得不那么常见了。尽管如此,它们仍然会导致严重的发病率和死亡率。因此,这些并发症的管理需要多学科的方法来计划和定制治疗方案。本文介绍了我们处理急性鼻窦炎引起的一系列颅内并发症的策略,并将我们的经验和结果与文献进行了比较。研究设计:单研究所经验,回顾性分析系列病例和文献综述。方法:纳入2016年至2020年在瑞士锡安医院耳鼻喉科接受ICS治疗的成人和儿童患者。记录了他们的症状、病史、临床和放射学表现、治疗和结果。结果:8例患者(男6例,女2例),年龄14 ~ 88岁。没有任何慢性鼻窦炎或复发性鼻窦炎病史。此外,很少有特定的鼻症状,但有神经或其他症状。计算机断层扫描(CT)和磁共振成像(MRI)证实所有ICS的诊断。在我们的队列中观察到所有类型的已知颅内并发症,鼻窦炎的扩展范围和严重程度都很广。针对每位患者,采用多学科方法进行个体化治疗。几乎所有患者的结果都是有利的,在随访中没有复发,也没有观察到神经系统后遗症。只有一名患者因晚期肺癌的致命并发症而死亡。结论:由于大量相关的发病率和死亡率,ICS仍然是一个具有挑战性的临床问题。这些并发症的发生率相对较低。缺乏治疗管理指南。早期发现和多学科结合是成功治疗的关键。
{"title":"Management Strategy of Intracranial Complications of Sinusitis: Our Experience and Review of the Literature.","authors":"Bassel Hallak,&nbsp;Salim Bouayed,&nbsp;Joseph André Ghika,&nbsp;Pedro S Teiga,&nbsp;Vincent Alvarez","doi":"10.1177/21526575221125031","DOIUrl":"https://doi.org/10.1177/21526575221125031","url":null,"abstract":"<p><strong>Objective: </strong>Sinusitis or rhinosinusitis is a very common disease worldwide, and in some cases, it leads to intracranial complications (ICS). These are more common in immunocompromised patients or with underlying comorbidities, but even healthy individuals, can be affected. Nowadays, ICS have become less common thanks to improved antibiotic therapies, radiological diagnostic methods, surgical techniques and skills. Nonetheless, they can still cause significant morbidity and mortality. For this reason, management of these complications requires a multidisciplinary approach to plan and customize treatment options. This paper presents our strategy in the management of a series of intracranial complications induced by acute sinusitis and compares our experience and outcomes with the literature.</p><p><strong>Study design: </strong>Single institute experience, retrospective analysis of cases series and literature review.</p><p><strong>Methods: </strong>Adult and child patients who were treated for ICS in the Department of Otorhinolaryngology at Sion Hospital, in Switzerland from 2016 to 2020 were included. Their symptoms, medical history, clinical and radiological findings, treatment, and outcome were documented.</p><p><strong>Results: </strong>Eight patients (6 males- 2 females) aged from 14 to 88 y.o., were enrolled. None had any previous history of chronic, or recurrent sinusitis. Moreover, very few presented specific rhinological symptoms, but with neurological or other symptoms. Computed tomography (CT) and Magnetic Resonance Imaging (MRI) were used to confirm the diagnosis of all ICS. All types of known intracranial complications were observed in our cohort with a wide range of extension and severity of sinusitis. A multidisciplinary approach with individual treatments was tailored to each patient. Outcomes were favorable in almost all patients with neither recurrence, nor neurological sequels being observed in the follow-up. Only one patient was lost due to fatal complications of advanced lung cancer.</p><p><strong>Conclusion: </strong>ICS remain a challenging clinical problem due to substantial associated morbidity and mortality. The incidence of these complications is relatively low. Therapeutical management guidelines are lacking. Early detection and multidisciplinary approach are key to successful treatment.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/e7/10.1177_21526575221125031.PMC9513574.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia. 在西弗吉尼亚州阿巴拉契亚地区对最初的 COVID-19 感染进行连续的康复血浆输注。
IF 2.3 Q1 OTORHINOLARYNGOLOGY Pub Date : 2022-06-30 eCollection Date: 2022-01-01 DOI: 10.1177/21526575221110488
Brian P Peppers, Aaron Shmookler, Johnathan Stanley, Lisa Giblin Sutton, Peter L Perrotta, Theodore Kieffer, David Skoner, Stacey Mahady, Callum Lewandrowski, Heath Damron, Alexander Horspool, Ankit Sakhjua, Paul McCarthy, Robert W Hostoffer

Purpose: The rapid spread of SARS-CoV-2, the virus that is responsible for causing COVID-19, has presented the medical community with another example of when convalescent plasma (CP) is still used today. The ability to standardize CP at the onset of a pandemic is unlikely to exist in a reliable and uniformly reproducible way. We hypothesized that CP of unknown strength given in a serial manner will promote health and reduce mortality in those inflicted with COVID-19.

Methods: Participants were given up to 8 CP-units depending on their condition upon entry into the study and their response.

Results: 102 out of 117 participants were given CP. The earlier a participant received CP corelated with survival (p = 0.0004). The number of CP-units given, throughout all the clinical severities, was not significant with outcomes, p = 0.3947. A higher number of CP-units given to the severe/critical participants (without biological immunosuppressants or restrictive lung disease) did correlate with survival p = 0.0116 (2.8 vs. 2 units). Lower platelets on admission corelated with mortality. Platelet levels increase correlated with CP infusions p < 0.0001.

Conclusion: This study supports the serial use of CP of unknown strength based on clinical response for those infected with COVID-19. The use of 3-4 units of CP was found to be statistically significant for survival for severe and critical participants without restrictive lung disease and chronic biological immunosuppression. Increased platelet levels after CP infusions supports that CP is promoting overall health regardless of outcomes.

目的:SARS-CoV-2(引起 COVID-19 的病毒)的迅速传播为医学界提供了另一个实例,说明当今仍在使用疗养血浆(CP)。在大流行开始时,不太可能以可靠和统一的可重复方式对 CP 进行标准化。我们假设,以连续方式给予未知强度的 CP 将促进 COVID-19 患者的健康并降低其死亡率:结果:117 位参与者中有 102 位接受了 CP 治疗:结果:117 名参与者中有 102 人获得了 CP。越早接受 CP 与存活率越相关(p = 0.0004)。在所有临床严重程度中,CP 单位的数量与结果无显著关系(p = 0.3947)。重症/危重症参与者(无生物免疫抑制剂或限制性肺部疾病)的 CP 单位数越多,与存活率的相关性越大,p = 0.0116(2.8 单位 vs. 2 单位)。入院时血小板较低与死亡率相关。血小板水平的升高与 CP 输注相关 p 结论:本研究支持根据临床反应对 COVID-19 感染者连续使用浓度未知的 CP。研究发现,对于没有限制性肺病和慢性生物免疫抑制的重症和危重症患者,使用 3-4 单位的 CP 对其存活率有显著的统计学意义。输注 CP 后血小板水平的增加证明,无论结果如何,CP 都能促进整体健康。
{"title":"Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia.","authors":"Brian P Peppers, Aaron Shmookler, Johnathan Stanley, Lisa Giblin Sutton, Peter L Perrotta, Theodore Kieffer, David Skoner, Stacey Mahady, Callum Lewandrowski, Heath Damron, Alexander Horspool, Ankit Sakhjua, Paul McCarthy, Robert W Hostoffer","doi":"10.1177/21526575221110488","DOIUrl":"10.1177/21526575221110488","url":null,"abstract":"<p><strong>Purpose: </strong>The rapid spread of SARS-CoV-2, the virus that is responsible for causing COVID-19, has presented the medical community with another example of when convalescent plasma (CP) is still used today. The ability to standardize CP at the onset of a pandemic is unlikely to exist in a reliable and uniformly reproducible way. We hypothesized that CP of unknown strength given in a serial manner will promote health and reduce mortality in those inflicted with COVID-19.</p><p><strong>Methods: </strong>Participants were given up to 8 CP-units depending on their condition upon entry into the study and their response.</p><p><strong>Results: </strong>102 out of 117 participants were given CP. The earlier a participant received CP corelated with survival (p = 0.0004). The number of CP-units given, throughout all the clinical severities, was not significant with outcomes, p = 0.3947. A higher number of CP-units given to the severe/critical participants (without biological immunosuppressants or restrictive lung disease) did correlate with survival p = 0.0116 (2.8 vs. 2 units). Lower platelets on admission corelated with mortality. Platelet levels increase correlated with CP infusions p < 0.0001.</p><p><strong>Conclusion: </strong>This study supports the serial use of CP of unknown strength based on clinical response for those infected with COVID-19. The use of 3-4 units of CP was found to be statistically significant for survival for severe and critical participants without restrictive lung disease and chronic biological immunosuppression. Increased platelet levels after CP infusions supports that CP is promoting overall health regardless of outcomes.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/dd/10.1177_21526575221110488.PMC9252015.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40566083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Outcomes Following Temperature-Controlled Radiofrequency Neurolysis for the Treatment of Chronic Rhinitis. 温控射频神经松解术治疗慢性鼻炎的长期疗效
IF 2.3 Q1 OTORHINOLARYNGOLOGY Pub Date : 2022-05-29 eCollection Date: 2022-01-01 DOI: 10.1177/21526575221096045
Dale Ehmer, Chad M McDuffie, J Bradley McIntyre, Bryan M Davis, Neelesh H Mehendale, John H Willis, Jeremy P Watkins, V Vasu Kakarlapudi

Background: Temperature-controlled radiofrequency neurolysis of the posterior nasal nerve has been shown to reduce the symptom burden of patients with chronic rhinitis.

Objectives: To evaluate the long-term safety and effectiveness of temperature-controlled radiofrequency neurolysis of the posterior nasal nerve for the treatment of chronic rhinitis.

Methods: A prospective extension of a 12-month single-arm study, where reflective total nasal symptom score (rTNSS) and the responses to a study-specific quality of life questionnaire and patient satisfaction survey were collected at 24 months.

Results: Forty-seven patients completed initial 12-month follow-up after treatment with the study device, of which 34 patients were reconsented and completed 24-month follow-up. The mean rTNSS of the long-term follow-up patients improved from 8.4 (95% confidence interval (CI), 7.7 to 9.0) at baseline to 2.9 (95% CI, 2.1 to 3.6), P < .001 at 24 months, a 65.5% improvement. On a 6-point scale (0-5), postnasal drip improved from a mean of 4.1 (95% CI, 3.6 to 4.6) to 2.1 (95% CI, 1.7 to 2.5) and chronic cough improved from 3.2 (95% CI, 2.7 to 3.6) to 0.9 (95% CI, 0.5 to 1.3) from baseline through 24 months; P < .001 for both measures. The proportion of patients achieving a minimal clinically important difference of 30% improvement from baseline at 24 months was 88.2% (95% CI, 73.4%-95.3%). At 24 months, 24% of patients were taking overall fewer and 15% taking overall more rhinitis medication classes than at baseline. Patients reported a higher quality of life in terms of sleep, well-being, and lower oral medication/nasal spray use at 24 months. There were no serious adverse events considered related to the procedure in the 12-24-month period.

Conclusion: Temperature-controlled radiofrequency neurolysis results in a significant and durable reduction in the symptom burden of chronic rhinitis and patients reported improved quality of life through 24 months postprocedure.

背景鼻后神经的温控射频神经松解术已被证明可以减轻慢性鼻炎患者的症状负担。目的评价鼻后神经温控射频松解术治疗慢性鼻炎的长期安全性和有效性。方法对一项为期12个月的单臂研究进行前瞻性扩展,在24个月时收集反映性总鼻症状评分(rTNSS)以及对研究特定生活质量问卷和患者满意度调查的回答。结果47例患者在使用该研究装置治疗后完成了12个月的初始随访,其中34例患者再次住院,完成了24个月的随访。长期随访患者的平均rTNSS从基线时的8.4(95%置信区间(CI),7.7~9.0)改善到2.9(95%可信区间,2.1~3.6),P < .001,改善65.5%。在6分制(0-5)中,从基线到24个月,鼻后滴注从平均4.1(95%置信区间,3.6至4.6)改善到2.1(95%可信区间,1.7至2.5),慢性咳嗽从3.2(95%可信范围,2.7至3.6)改善到0.9(95%可信范围,0.5至1.3);P < .001。在24个月时,与基线相比,获得30%改善的最小临床重要差异的患者比例为88.2%(95%CI,73.4%-95.3%)。在24个月中,24%的患者总体上比基线减少了鼻炎药物类别,15%的患者总体增加了鼻炎药物类别。患者报告称,在24个月时,他们在睡眠、健康和口服药物/鼻喷雾剂使用方面的生活质量更高。在12-24个月期间,没有发生与手术相关的严重不良事件。结论温控射频神经松解术可显著、持久地减轻慢性鼻炎的症状负担,术后24个月患者的生活质量得到改善。
{"title":"Long-term Outcomes Following Temperature-Controlled Radiofrequency Neurolysis for the Treatment of Chronic Rhinitis.","authors":"Dale Ehmer, Chad M McDuffie, J Bradley McIntyre, Bryan M Davis, Neelesh H Mehendale, John H Willis, Jeremy P Watkins, V Vasu Kakarlapudi","doi":"10.1177/21526575221096045","DOIUrl":"10.1177/21526575221096045","url":null,"abstract":"<p><strong>Background: </strong>Temperature-controlled radiofrequency neurolysis of the posterior nasal nerve has been shown to reduce the symptom burden of patients with chronic rhinitis.</p><p><strong>Objectives: </strong>To evaluate the long-term safety and effectiveness of temperature-controlled radiofrequency neurolysis of the posterior nasal nerve for the treatment of chronic rhinitis.</p><p><strong>Methods: </strong>A prospective extension of a 12-month single-arm study, where reflective total nasal symptom score (rTNSS) and the responses to a study-specific quality of life questionnaire and patient satisfaction survey were collected at 24 months.</p><p><strong>Results: </strong>Forty-seven patients completed initial 12-month follow-up after treatment with the study device, of which 34 patients were reconsented and completed 24-month follow-up. The mean rTNSS of the long-term follow-up patients improved from 8.4 (95% confidence interval (CI), 7.7 to 9.0) at baseline to 2.9 (95% CI, 2.1 to 3.6), <i>P </i>< .001 at 24 months, a 65.5% improvement. On a 6-point scale (0-5), postnasal drip improved from a mean of 4.1 (95% CI, 3.6 to 4.6) to 2.1 (95% CI, 1.7 to 2.5) and chronic cough improved from 3.2 (95% CI, 2.7 to 3.6) to 0.9 (95% CI, 0.5 to 1.3) from baseline through 24 months; <i>P </i>< .001 for both measures. The proportion of patients achieving a minimal clinically important difference of 30% improvement from baseline at 24 months was 88.2% (95% CI, 73.4%-95.3%). At 24 months, 24% of patients were taking overall fewer and 15% taking overall more rhinitis medication classes than at baseline. Patients reported a higher quality of life in terms of sleep, well-being, and lower oral medication/nasal spray use at 24 months. There were no serious adverse events considered related to the procedure in the 12-24-month period.</p><p><strong>Conclusion: </strong>Temperature-controlled radiofrequency neurolysis results in a significant and durable reduction in the symptom burden of chronic rhinitis and patients reported improved quality of life through 24 months postprocedure.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2022-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44952618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Practical Clinical Protocol for Monitoring Patients with Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyposis Treated with Biologics. 生物制剂治疗严重不受控制的慢性鼻窦炎合并鼻息肉的临床监测实用方案。
IF 2.2 Q3 Medicine Pub Date : 2022-01-31 eCollection Date: 2022-01-01 DOI: 10.1177/21526567221074335
Stefano Millarelli, Antonella Loperfido, Fulvio Mammarella, Cristina Giorgione, Alessandra Celebrini, Massimiliano Del Ninno, Gianluca Bellocchi

Objectives: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a pathological condition which leads to high healthcare-related costs and low quality of life for patients. The introduction of new biological therapies (monoclonal antibodies, MAbs) in CRSwNP patients has allowed new therapeutic options for non-responders to conventional therapies and Dupilumab represents the first approved biological agent. The aim of this paper is to provide a practical clinical multidisciplinary protocol which might help clinicians involved in this field to monitor the clinical outcomes.

Methods: Our centre of Rhinology and Rhino-Allergology has developed a dedicated collection form to observe the outcomes of patients treated with Dupilumab. Our research started from the indications given in EPOS 2020 as main reference. We then implemented these references in an electronic database trying to apply Evidence Based Medicine (EBM) in current clinical practice.

Results: The result consists of three parts: an anamnestic collection data, a clinician reported outcome and two patient reported outcomes (PROMs) questionnaire, the visual analogue scale (VAS) and the Sino-Nasal Outcome Test-22 (SNOT-22). The tables we propose should provide an adequate correlation with the patients' adherence to therapy and their treatment outcomes. Such periodical evaluation (after a month, after 3 months, after 6 months and at one year) should quickly allow to monitor if the patient is correctly assuming the therapy and the eventual objective improvements.

Conclusions: We propose a practical monitoring protocol formulated to analyse both objective and subjective aspects of patients with severe uncontrolled CRSwNP treated with MAbs, thus helping to define in future a better comparison between the clinical results of different institutes.

目的:慢性鼻窦炎伴鼻息肉病(CRSwNP)是一种导致患者高医疗相关费用和低生活质量的病理状况。在CRSwNP患者中引入新的生物疗法(单克隆抗体,mab),为对传统疗法无反应的患者提供了新的治疗选择,而Dupilumab是首个获批的生物药物。本文的目的是提供一个实用的临床多学科协议,可以帮助临床医生参与该领域的临床监测临床结果。方法:我们的鼻科学和鼻过敏学中心已经开发了一个专门的收集表格来观察杜匹单抗治疗的患者的结果。我们的研究以EPOS 2020给出的适应症为主要参考。然后,我们在电子数据库中实现这些参考文献,试图将循证医学(EBM)应用于当前的临床实践。结果:结果由三部分组成:一份记忆收集数据、一份临床报告结果和两份患者报告结果(PROMs)问卷、视觉模拟量表(VAS)和Sino-Nasal outcome Test-22 (SNOT-22)。我们提出的表格应提供足够的相关性与患者的治疗依从性和他们的治疗结果。这种定期评估(1个月后、3个月后、6个月后和1年后)应能迅速监测患者是否正确接受治疗以及最终的客观改善。结论:我们提出了一种实用的监测方案,以分析单克隆抗体治疗严重不受控制的CRSwNP患者的客观和主观方面,从而有助于确定未来不同机构的临床结果之间更好的比较。
{"title":"A Practical Clinical Protocol for Monitoring Patients with Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyposis Treated with Biologics.","authors":"Stefano Millarelli,&nbsp;Antonella Loperfido,&nbsp;Fulvio Mammarella,&nbsp;Cristina Giorgione,&nbsp;Alessandra Celebrini,&nbsp;Massimiliano Del Ninno,&nbsp;Gianluca Bellocchi","doi":"10.1177/21526567221074335","DOIUrl":"https://doi.org/10.1177/21526567221074335","url":null,"abstract":"<p><strong>Objectives: </strong>Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a pathological condition which leads to high healthcare-related costs and low quality of life for patients. The introduction of new biological therapies (monoclonal antibodies, MAbs) in CRSwNP patients has allowed new therapeutic options for non-responders to conventional therapies and Dupilumab represents the first approved biological agent. The aim of this paper is to provide a practical clinical multidisciplinary protocol which might help clinicians involved in this field to monitor the clinical outcomes.</p><p><strong>Methods: </strong>Our centre of Rhinology and Rhino-Allergology has developed a dedicated collection form to observe the outcomes of patients treated with Dupilumab. Our research started from the indications given in EPOS 2020 as main reference. We then implemented these references in an electronic database trying to apply Evidence Based Medicine (EBM) in current clinical practice.</p><p><strong>Results: </strong>The result consists of three parts: an anamnestic collection data, a clinician reported outcome and two patient reported outcomes (PROMs) questionnaire, the visual analogue scale (VAS) and the Sino-Nasal Outcome Test-22 (SNOT-22). The tables we propose should provide an adequate correlation with the patients' adherence to therapy and their treatment outcomes. Such periodical evaluation (after a month, after 3 months, after 6 months and at one year) should quickly allow to monitor if the patient is correctly assuming the therapy and the eventual objective improvements.</p><p><strong>Conclusions: </strong>We propose a practical monitoring protocol formulated to analyse both objective and subjective aspects of patients with severe uncontrolled CRSwNP treated with MAbs, thus helping to define in future a better comparison between the clinical results of different institutes.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2022-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/91/10.1177_21526567221074335.PMC8808004.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39597591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Recurrent Bilateral Lime Disease in a Young Female- Case Report. 年轻女性双侧复发性石灰病1例报告。
IF 2.2 Q3 Medicine Pub Date : 2022-01-24 eCollection Date: 2022-01-01 DOI: 10.1177/21526567221074944
Lakshmi Nagireddi, Rachel Raimondo, Robert Hostoffer

Introduction: Lime phytodermatitis, also known as margarita dermatitis, is a condition that results in a skin rash after sunlight exposure when handling certain plants. Misdiagnosis is common due to its resemblance to skin burns or allergic contact dermatitis. Detailed history and disease recognition is important to provide accurate treatment recommendations.

Case report: A 32-year-old woman presented with a recurrent rash on her hands that would only occur in the summer months. She was previously misdiagnosed as allergic contact dermatitis. History revealed yearly vacations involving margaritas and squeezing lime into her drinks followed by exposure to sunlight. A presumptive diagnosis of lime phytodermatitis was made and she was advised to avoid contact with limes followed by exposure to direct sunlight.

Discussion: Lime phytodermatitis occurs after direct contact with lime and sunlight exposure. A phototoxic compound found in limes, Furocoumarin, has been implicated as a cause for lime disease. Detailed history is important in establishing a diagnosis of lime disease. Treatment is symptomatic with topical corticosteroids, avoidance of furocoumarin-containing objects, cold compresses, and subsequent UV exposure.

Conclusion: We present the first case of recurrent, bilateral phytodermatitis in a 32-year-old woman following contact with limes and subsequent sunlight exposure in the summer months.

简介:柠檬植物性皮炎,也被称为玛格丽塔皮炎,是一种在处理某些植物时暴露在阳光下导致皮肤皮疹的情况。误诊是常见的,因为它类似于皮肤烧伤或过敏性接触性皮炎。详细的病史和疾病识别对于提供准确的治疗建议非常重要。病例报告:一名32岁妇女表现为手部复发性皮疹,这种皮疹只会在夏季出现。她之前被误诊为过敏性接触性皮炎。历史表明,她每年的假期都要喝玛格丽塔酒,在饮料中挤上酸橙,然后晒晒太阳。推定诊断为酸橙植物性皮炎,并建议她避免接触酸橙,然后直接暴露在阳光下。讨论:石灰植物性皮炎发生在直接接触石灰和阳光照射后。在石灰中发现的一种光毒性化合物,呋喃香豆素,被认为是石灰病的原因。详细的病史对确定石灰病的诊断很重要。对症治疗是局部使用皮质类固醇,避免使用含有呋喃香豆素的物品,冷敷,随后进行紫外线照射。结论:我们报告了第一例复发性双侧植物性皮炎,患者为一名32岁女性,在夏季接触柠檬和随后的阳光照射后。
{"title":"Recurrent Bilateral Lime Disease in a Young Female- Case Report.","authors":"Lakshmi Nagireddi,&nbsp;Rachel Raimondo,&nbsp;Robert Hostoffer","doi":"10.1177/21526567221074944","DOIUrl":"https://doi.org/10.1177/21526567221074944","url":null,"abstract":"<p><strong>Introduction: </strong>Lime phytodermatitis, also known as margarita dermatitis, is a condition that results in a skin rash after sunlight exposure when handling certain plants. Misdiagnosis is common due to its resemblance to skin burns or allergic contact dermatitis. Detailed history and disease recognition is important to provide accurate treatment recommendations.</p><p><strong>Case report: </strong>A 32-year-old woman presented with a recurrent rash on her hands that would only occur in the summer months. She was previously misdiagnosed as allergic contact dermatitis. History revealed yearly vacations involving margaritas and squeezing lime into her drinks followed by exposure to sunlight. A presumptive diagnosis of lime phytodermatitis was made and she was advised to avoid contact with limes followed by exposure to direct sunlight.</p><p><strong>Discussion: </strong>Lime phytodermatitis occurs after direct contact with lime and sunlight exposure. A phototoxic compound found in limes, Furocoumarin, has been implicated as a cause for lime disease. Detailed history is important in establishing a diagnosis of lime disease. Treatment is symptomatic with topical corticosteroids, avoidance of furocoumarin-containing objects, cold compresses, and subsequent UV exposure.</p><p><strong>Conclusion: </strong>We present the first case of recurrent, bilateral phytodermatitis in a 32-year-old woman following contact with limes and subsequent sunlight exposure in the summer months.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2022-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/e8/10.1177_21526567221074944.PMC8796115.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39872892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurally Mediated Syncope Triggered by COVID-19 Nasopharyngeal Swab Specimen Collection: A Case Report. COVID-19鼻咽拭子标本采集引发神经介导晕厥1例报告
IF 2.2 Q3 Medicine Pub Date : 2022-01-19 eCollection Date: 2022-01-01 DOI: 10.1177/21526567211073794
William R Bloom, Thomas D Bloom

There are few reports describing adverse events associated with nasopharyngeal swab specimen collection in patients tested for SARS-Cov-2 (COVID-19). Despite the lack of data, providers should be aware of complications associated with swab collection. Instances of nasopharyngeal swab as a syncope trigger are mostly anecdotal and not well described in the medical literature. We present a case of neural reflex mediated syncope associated with the nasopharyngeal swab specimen collection process in a healthy patient undergoing COVID-19 testing prior to elective surgery. This response may be mediated by the trigeminocardiac reflex or via glossopharyngeal nerve stimulation. Less invasive collection practices, such as saliva sampling, may be warranted, particularly in those predisposed to syncopal episodes.

很少有报告描述在接受SARS-Cov-2 (COVID-19)检测的患者中采集鼻咽拭子标本相关的不良事件。尽管缺乏数据,但提供者应意识到与拭子收集相关的并发症。鼻咽拭子作为晕厥触发器的实例大多是轶事,并没有很好地描述在医学文献中。我们报告了一例神经反射介导的晕厥与鼻咽拭子标本采集过程相关的病例,该患者在择期手术前接受了COVID-19检测。这种反应可能是由三叉心反射或通过舌咽神经刺激介导的。较少侵入性的收集方法,如唾液取样,可能是必要的,特别是那些易晕厥发作的患者。
{"title":"Neurally Mediated Syncope Triggered by COVID-19 Nasopharyngeal Swab Specimen Collection: A Case Report.","authors":"William R Bloom,&nbsp;Thomas D Bloom","doi":"10.1177/21526567211073794","DOIUrl":"https://doi.org/10.1177/21526567211073794","url":null,"abstract":"<p><p>There are few reports describing adverse events associated with nasopharyngeal swab specimen collection in patients tested for SARS-Cov-2 (COVID-19). Despite the lack of data, providers should be aware of complications associated with swab collection. Instances of nasopharyngeal swab as a syncope trigger are mostly anecdotal and not well described in the medical literature. We present a case of neural reflex mediated syncope associated with the nasopharyngeal swab specimen collection process in a healthy patient undergoing COVID-19 testing prior to elective surgery. This response may be mediated by the trigeminocardiac reflex or via glossopharyngeal nerve stimulation. Less invasive collection practices, such as saliva sampling, may be warranted, particularly in those predisposed to syncopal episodes.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1a/4f/10.1177_21526567211073794.PMC8796065.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39872891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Chronic Spontaneous Urticaria Triggered by the AstraZeneca/Oxford COVID-19 Vaccine with Achieved Remission: A Case Report. 阿斯利康/牛津COVID-19疫苗引发的慢性自发性荨麻疹获得缓解:一例报告
IF 2.2 Q3 Medicine Pub Date : 2022-01-10 eCollection Date: 2022-01-01 DOI: 10.1177/21526567211068458
Stephanie G Brooks, Anna M De Jong, Mina Abbaslou, Gordon Sussman

New adverse reactions to the COVID-19 vaccines are being identified as vaccination rates increase worldwide. Recently, there have been two reports of Moderna (mRNA-1273) vaccine induced relapse of chronic spontaneous urticaria (CSU) that was previously well controlled. Herein, we report a case of AstraZeneca/Oxford (ChAdOx1) vaccine triggered CSU in a patient with no history of CSU with achieved remission.

随着全球疫苗接种率的上升,正在发现新的COVID-19疫苗不良反应。最近,有两篇关于Moderna (mRNA-1273)疫苗诱导慢性自发性荨麻疹(CSU)复发的报道,而这些疾病以前得到了很好的控制。在此,我们报告了一例阿斯利康/牛津(ChAdOx1)疫苗引发的CSU患者,该患者无CSU病史,但已获得缓解。
{"title":"Chronic Spontaneous Urticaria Triggered by the AstraZeneca/Oxford COVID-19 Vaccine with Achieved Remission: A Case Report.","authors":"Stephanie G Brooks,&nbsp;Anna M De Jong,&nbsp;Mina Abbaslou,&nbsp;Gordon Sussman","doi":"10.1177/21526567211068458","DOIUrl":"https://doi.org/10.1177/21526567211068458","url":null,"abstract":"<p><p>New adverse reactions to the COVID-19 vaccines are being identified as vaccination rates increase worldwide. Recently, there have been two reports of Moderna (mRNA-1273) vaccine induced relapse of chronic spontaneous urticaria (CSU) that was previously well controlled. Herein, we report a case of AstraZeneca/Oxford (ChAdOx1) vaccine triggered CSU in a patient with no history of CSU with achieved remission.</p>","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39825490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Pollen Allergy Screening with Allergen-Specific and Total Immunoglobulin E Titers 用变应原特异性和总免疫球蛋白E滴度筛选花粉变态反应
IF 2.2 Q3 Medicine Pub Date : 2022-01-01 DOI: 10.1177/21526575221079260
H. Yokoi, Yuma Matsumoto, M. Kawada, Hiroyuki Sakurai, Koichiro Saito
Background Allergic rhinitis is a typical type I hypersensitivity reaction, commonly caused by inhalant allergens. Accurate identification of the causative antigen is important for rapid diagnosis and treatment initiation. Objective This study examined the efficiency of serum-based allergen-specific immunoglobulin E and total immunoglobulin E antibody titers in screening for pollen allergy. We also examined the effect of cross-reactive carbohydrate determinants on specific immunoglobulin E titers in screening for pollen allergy, one of the causes of false positivity in specific immunoglobulin E measurements. Methods A questionnaire was used to evaluate the symptoms of pollinosis among participants who underwent a medical examination. One hundred and thirty-two participants reported pollen allergy symptoms and 127 reported an absence of symptoms. Specific immunoglobulin E levels were measured using the AlaSTAT 3g Allergy method. Seventeen components, including four types of cross-reactive carbohydrate determinant-specific immunoglobulin E antibodies, were measured and evaluated comparatively. Results The sensitivity and specificity of the tests in predicting the presence or absence of pollen allergy were analyzed. The values of the areas under the curves for immunoglobulin E antibody levels against cedar, cypress, orchard grass, and ragweed pollen were 0.87, 0.82, 0.63, and 0.56, respectively. A cross-reactive carbohydrate determinant-related false-positive effect on the pollen specific immunoglobulin E titer was noted in pollen screening. Conclusion Cedar pollen-specific immunoglobulin E titers showed sufficient accuracy for use in pollen allergy screening. The study of cross-reactive carbohydrate determinants suggested that subjects who tested positive for pollen often had false-positive results due to the impact of cross-reactive carbohydrate determinants.
背景过敏性鼻炎是一种典型的I型超敏反应,主要由吸入性过敏原引起。病原体抗原的准确鉴定对于快速诊断和治疗的开始非常重要。目的检测血清过敏原特异性免疫球蛋白E和总免疫球蛋白抗体滴度在花粉过敏筛查中的有效性。我们还研究了交叉反应性碳水化合物决定簇对花粉过敏筛查中特异性免疫球蛋白E滴度的影响,花粉过敏是特异性免疫球蛋白E测量假阳性的原因之一。方法采用问卷调查法,对接受医学检查的受试者进行花粉症症状评估。132名参与者报告了花粉过敏症状,127名参与者报告没有症状。使用AlaSTAT 3g Allergy方法测量特异性免疫球蛋白E水平。对17种成分,包括四种类型的交叉反应性碳水化合物决定簇特异性免疫球蛋白E抗体进行了测量和比较评估。结果分析了这些试验在预测是否存在花粉过敏方面的敏感性和特异性。针对雪松、柏树、果园草和豚草花粉的免疫球蛋白E抗体水平的曲线下面积值分别为0.87、0.82、0.63和0.56。在花粉筛选中注意到与交叉反应性碳水化合物决定簇相关的对花粉特异性免疫球蛋白E滴度的假阳性影响。结论雪松花粉特异性免疫球蛋白E滴度在花粉过敏筛查中具有足够的准确性。对交叉反应性碳水化合物决定因素的研究表明,由于交叉反应性糖类决定因素的影响,花粉检测呈阳性的受试者往往会出现假阳性结果。
{"title":"Pollen Allergy Screening with Allergen-Specific and Total Immunoglobulin E Titers","authors":"H. Yokoi, Yuma Matsumoto, M. Kawada, Hiroyuki Sakurai, Koichiro Saito","doi":"10.1177/21526575221079260","DOIUrl":"https://doi.org/10.1177/21526575221079260","url":null,"abstract":"Background Allergic rhinitis is a typical type I hypersensitivity reaction, commonly caused by inhalant allergens. Accurate identification of the causative antigen is important for rapid diagnosis and treatment initiation. Objective This study examined the efficiency of serum-based allergen-specific immunoglobulin E and total immunoglobulin E antibody titers in screening for pollen allergy. We also examined the effect of cross-reactive carbohydrate determinants on specific immunoglobulin E titers in screening for pollen allergy, one of the causes of false positivity in specific immunoglobulin E measurements. Methods A questionnaire was used to evaluate the symptoms of pollinosis among participants who underwent a medical examination. One hundred and thirty-two participants reported pollen allergy symptoms and 127 reported an absence of symptoms. Specific immunoglobulin E levels were measured using the AlaSTAT 3g Allergy method. Seventeen components, including four types of cross-reactive carbohydrate determinant-specific immunoglobulin E antibodies, were measured and evaluated comparatively. Results The sensitivity and specificity of the tests in predicting the presence or absence of pollen allergy were analyzed. The values of the areas under the curves for immunoglobulin E antibody levels against cedar, cypress, orchard grass, and ragweed pollen were 0.87, 0.82, 0.63, and 0.56, respectively. A cross-reactive carbohydrate determinant-related false-positive effect on the pollen specific immunoglobulin E titer was noted in pollen screening. Conclusion Cedar pollen-specific immunoglobulin E titers showed sufficient accuracy for use in pollen allergy screening. The study of cross-reactive carbohydrate determinants suggested that subjects who tested positive for pollen often had false-positive results due to the impact of cross-reactive carbohydrate determinants.","PeriodicalId":45192,"journal":{"name":"Allergy & Rhinology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42531688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Allergy & Rhinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1